MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.anai.2025.08.007

Медицинская библиотека · Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology · 2025

Adherence to inhaled corticosteroid medications after an asthma exacerbation and the risk of subsequent exacerbations.

Khezrian Mina, Kerkhof Marjan, Le Tham T, Harrison Tim, Wu Tianshi David, Cook Bill, Hedberg Jonatan, Rhodes Kirsty, Zubizarreta Nicole, Enxing Joshua, Tran Trung N

СтатьяПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

BACKGROUND

Data on the duration of improved adherence to controller medications after an exacerbation and its impact on asthma outcomes are inconsistent.

OBJECTIVE

To describe levels and changes in adherence to inhaled corticosteroid (ICS)-containing medication after a severe exacerbation and the association with future exacerbation risk.

METHODS

This retrospective cohort study used data from Optum's deidentified Clinformatics Data Mart Database (October 2015-December 2023). Patients with asthma, 1 or more severe exacerbations, and adherence to ICS-containing therapy (proportion of days covered [PDC]) of less than 80% in the 3 months before an exacerbation were included. Primary and secondary end points were the annualized asthma exacerbation rate and the time to the first subsequent severe exacerbation. End points were compared between patients who improved adherence in the 3 months after the qualifying exacerbation to 80% or more and those who remained at PDC less than 80%. Inverse probability of treatment weighting accounted for between-group imbalances.

RESULTS

Of 68,398 participants, 85% stayed less than 80% PDC, whereas 15% improved to PDC 80% or more at 3 months after the qualifying exacerbation. Of patients with improved PDC, only 40%, 31%, and 22% maintained PDC 80% or more at 3 to 6, 6 to 9, and 9 to 12 months after the qualifying exacerbation, respectively. Improving adherence to PDC 80% or more in the 3 months after the qualifying exacerbation did not reduce annualized asthma exacerbation rate (rate ratio: 0.958 [95% CI 0.912-1.007]) or increase the time to the next exacerbation (hazard ratio: 0.997 [95% CI 0.954-1.041]). Results were consistent in sensitivity analyses.

CONCLUSION

Improvement in adherence to ICS-containing therapy after a severe exacerbation was transient and not beneficial for exacerbation outcomes, indicating a need to consider alternative treatment strategies in patients with asthma.

Для цитирования: Khezrian Mina, Kerkhof Marjan, Le Tham T, Harrison Tim, Wu Tianshi David, Cook Bill, Hedberg Jonatan, Rhodes Kirsty, Zubizarreta Nicole, Enxing Joshua, Tran Trung N. Adherence to inhaled corticosteroid medications after an asthma exacerbation and the risk of subsequent exacerbations.. Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology. 2025. DOI: 10.1016/j.anai.2025.08.007.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.